Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-04-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
独立董事对担保等事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various matters related to the company's 2022 annual report and related issues such as external guarantees, internal control self-assessment, auditor reappointment, profit distribution plan, remuneration, use of idle raised funds, and shareholder return planning. It references the 2022 annual report but does not contain the full annual report itself or detailed financial statements. The document is relatively short (2577 characters) and serves as an opinion or commentary on the annual report and related governance matters. This fits best with the category of Board/Management Information (MANG), as it involves independent directors' opinions on board meeting matters and governance-related disclosures rather than the full annual report or audit report. It is not a report publication announcement since it contains substantive independent opinions rather than just a notice of report availability.
2023-04-17 Chinese
年度股东大会通知
AGM Information Classification · 100% confidence The document is a detailed announcement about the convening of the 2022 Annual General Meeting (AGM) of the company 海思科医药集团股份有限公司. It includes information about the meeting date, voting procedures, proposals to be voted on (including the 2022 financial report, annual report, board work report, profit distribution plan, etc.), registration details, and proxy voting instructions. The document does not contain the actual financial reports or results but rather the notice and procedural information for the AGM. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself. The document length is 4093 characters, which is consistent with a detailed AGM notice rather than a full annual report or financial statement. Therefore, the correct classification is AGM Information (AGM-R).
2023-04-17 Chinese
独立董事2022年度述职报告（YAN JONATHAN JUN）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of a company, describing their duties, attendance at meetings, opinions on board matters, committee work, and compliance with regulations for the year 2022. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or certification. It focuses on board/management information, specifically the independent director's annual work report. This fits the category of Board/Management Information (MANG). The document length and content confirm it is a substantive report, not a mere announcement or certification.
2023-04-17 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of 海思科医药集团股份有限公司, which indicates it is a summary of the full annual report. It contains detailed financial data for the year 2022, including total assets, net profit, revenue, and quarterly financial data. It also includes company business descriptions, product information, and shareholder details. The length of the document (7732 characters) and the presence of substantive financial data and analysis confirm it is a financial report rather than a mere announcement. The document is not a full annual report but a summary derived from the full annual report, which is typical for annual report filings. Therefore, the most appropriate classification is Annual Report (10-K). FY 2022
2023-04-17 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to use part of its idle raised funds temporarily to supplement working capital. It details the approval by the board and supervisory committee, references regulatory guidelines on the management and use of raised funds, and includes opinions from independent directors and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather focuses on the use of capital raised through a non-public stock issuance. It is a regulatory announcement about capital usage rather than a financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content about capital usage, not just a brief report publication announcement or certification. Hence, CAP is the most appropriate classification with high confidence.
2023-04-17 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告全文" which translates to "2022 Annual Report Full Text" for 海思科医药集团股份有限公司 (Haisco Pharmaceutical Group Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes signed financial statements and an audit report, which are components of a full annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-17 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.